Vutrisiran Met Primary and All Secondary Endpoints | ALNY Message Board Posts


Alnylam Pharmaceuticals

  ALNY website
  • TECH UPDATE, Sunday, 9/26/2021, 12 p.m. EDT

    While it took longer than projected, knock on wood, yesterday's maintenance work appears to have been a success.  Most of the heavy lifting has been done, including upgrading several hard drives and back end switches to improve overall system storage, security and connectivity.  Work will continue on a moderated basis over the next several weeks to ensure a smooth transition.  Our primary infrastructure technician will continue to monitor and tweak the upgraded equipment until things settle into a stable, manageable routine.  If we hit any snags along the way (which unfortunately I can't rule out) please accept our apologies in advance.  The goal, of course, is to improve user experience for all our customers and that's what we remain focused on and committed to delivering.  Thanks in advance for your continued patience, understanding & support.  

ALNY   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  34975 of 35000  at  4/19/2021 2:22:49 PM  by

Steve_382


Vutrisiran Met Primary and All Secondary Endpoints

It's still a biotech, so nobody cares right now.
 
 
 
·15 min read

– At 9 Months, Vutrisiran Met Primary and All Secondary Endpoints, with Statistically Significant Improvements in Neuropathy, Quality of Life (QoL), and Gait Speed, Relative to Placebo –

– In Majority of Patients, Vutrisiran Showed Reversal of Polyneuropathy Manifestations with Improvements in Neuropathy and QoL, Relative to Baseline –

– Vutrisiran Also Met Key Exploratory Endpoints Including Measures of Nutritional Status, Overall Disability, and Cardiac Biomarker (NT-proBNP), Relative to Placebo –

– Vutrisiran Demonstrated Encouraging Safety and Tolerability Profile –

– In Addition, Alnylam Submits New Drug Application (NDA) with U.S. Food and Drug Administration (FDA) for Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR (hATTR) Amyloidosis in Adults –

– Company to Host Conference Call Today at 4:00 pm ET –

 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0  
   Views: 0 []
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


Financial Market Data provided by
.
Loading...